SLC14A1: A Potential Drug Target and Biomarker (G6563)

Target Name: SLC14A1

NCBI ID: G6563

SLC14A1: A Potential Drug Target and Biomarker

SLC14A1 is a protein that is expressed in many different tissues throughout the body. It is a member of the Kidd blood group antigens, which are a group of surface antigens that are found on the surface of red blood cells. These antigens are important for the development of blood clotting mechanisms, and they are also used as potential drug targets or biomarkers.

One of the unique features of SLC14A1 is its structure. It is a transmembrane protein, which means that it spans the cell membrane and is involved in many different cellular processes. It is made up of four distinct chains that are held together by disulfide bonds. The chains are composed of a variable region, a constant region, a variable region, and a variable region. The variable region is the region that is responsible for the antigenic variation, and it is the region that is used to create unique combinations of surface antigens.

SLC14A1 is a glycoprotein, which means that it is composed of both protein and carbohydrate. It has a molecular weight of approximately 17 kDa, which makes it a small protein that is easily targeted by drugs. It is also a good candidate for biomarkers because it is relatively stable and can be easily purified from cells.

SLC14A1 is expressed in many different tissues throughout the body, including the liver, spleen, kidney, and heart. It is also expressed in the placenta, which is the tissue that provides nutrients and oxygen to the developing fetus. SLC14A1 is involved in many different cellular processes, including cell signaling, inflammation, and immune response. It is also involved in the development of blood clotting mechanisms, which is why it is important for drug development.

One of the potential benefits of SLC14A1 as a drug target is its ability to interact with other proteins. SLC14A1 has been shown to interact with several different proteins, including the protein PDGF-BB and the protein NF-kappa-B. This suggests that it may be a useful target for drugs that are designed to intervene in these signaling pathways. SLC14A1 may also be a useful biomarker for monitoring the effectiveness of these drugs.

Another potential benefit of SLC14A1 as a drug target is its ability to modulate cellular processes that are associated with disease. SLC14A1 has been shown to be involved in many different cellular processes that are associated with disease, including inflammation, fibrosis, and blood clotting. This suggests that it may be a useful target for drugs that are designed to modulate these processes. SLC14A1 may also be a useful biomarker for monitoring the effectiveness of these drugs.

Overall, SLC14A1 is a protein that is expressed in many different tissues throughout the body and has been shown to be involved in many different cellular processes. Its unique structure and ability to interact with other proteins make it a promising candidate for drug development. SLC14A1 may also be a useful biomarker for monitoring the effectiveness of these drugs. Further research is needed to fully understand its potential role in disease.

Protein Name: Solute Carrier Family 14 Member 1 (Kidd Blood Group)

Functions: Mediates the transport of urea driven by a concentration gradient across the cell membrane of erythrocytes (PubMed:7989337, PubMed:10514515, PubMed:7797558, PubMed:8997401). Also mediates the transport of urea across the cell membrane of the renal inner medullary collecting duct which is critical to the urinary concentrating mechanism (By similarity). Facilitates water transport in erythrocytes (By similarity)

More Common Targets